UX GIP001
Alternative Names: GABAergic interneuron progenitor cell therapy - Shanghai UniXell Biotechnology; UX-GIP001; UX-GIP001 cell therapy - Shanghai UniXell BiotechnologyLatest Information Update: 03 Aug 2026
At a glance
- Originator Shanghai UniXell Biotechnology
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Partial epilepsies; Temporal-lobe-epilepsy
Most Recent Events
- 03 Aug 2026 Shanghai UniXell Biotechnology plans a phase I trial for Epilepsy in China (Intracerebral) in August 2026 (NCT07572812)
- 13 Mar 2026 Preclinical trials in Partial epilepsies in China (Intracerebral) before March 2026
- 13 Mar 2026 US FDA approves IND application for UX GIP001 in Partial epilepsies